NO854518L - Nye fenoksypropanolaminsalter og farmasoeytiske preparater derav. - Google Patents
Nye fenoksypropanolaminsalter og farmasoeytiske preparater derav.Info
- Publication number
- NO854518L NO854518L NO854518A NO854518A NO854518L NO 854518 L NO854518 L NO 854518L NO 854518 A NO854518 A NO 854518A NO 854518 A NO854518 A NO 854518A NO 854518 L NO854518 L NO 854518L
- Authority
- NO
- Norway
- Prior art keywords
- alprenolol
- tablets
- salts
- salt
- benzoate
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 10
- UJUKHOATWVVDER-UHFFFAOYSA-N 1-amino-1-phenoxypropan-1-ol Chemical class CCC(N)(O)OC1=CC=CC=C1 UJUKHOATWVVDER-UHFFFAOYSA-N 0.000 title 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 claims description 50
- 229960002213 alprenolol Drugs 0.000 claims description 43
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 22
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 11
- 239000005711 Benzoic acid Substances 0.000 claims description 10
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 10
- URFIUJMADXJBKL-UHFFFAOYSA-N benzoic acid;1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol Chemical group OC(=O)C1=CC=CC=C1.CC(C)NCC(O)COC1=CC=CC=C1CC=C URFIUJMADXJBKL-UHFFFAOYSA-N 0.000 claims description 10
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 10
- 239000011976 maleic acid Substances 0.000 claims description 10
- 235000010233 benzoic acid Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 31
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 15
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 210000003238 esophagus Anatomy 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- RRCPAXJDDNWJBI-UHFFFAOYSA-N alprenolol hydrochloride Chemical compound [H+].[Cl-].CC(C)NCC(O)COC1=CC=CC=C1CC=C RRCPAXJDDNWJBI-UHFFFAOYSA-N 0.000 description 5
- 229960004977 anhydrous lactose Drugs 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000000622 irritating effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920000945 Amylopectin Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 244000165918 Eucalyptus papuana Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010030201 Oesophageal ulcer Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960000852 alprenolol hydrochloride Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- JEJBJBKVPOWOQK-UHFFFAOYSA-N emepronium Chemical compound C=1C=CC=CC=1C(CC(C)[N+](C)(C)CC)C1=CC=CC=C1 JEJBJBKVPOWOQK-UHFFFAOYSA-N 0.000 description 1
- 229960002236 emepronium Drugs 0.000 description 1
- 208000028299 esophageal disease Diseases 0.000 description 1
- 208000019064 esophageal ulcer Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- CMUHZRATLMUDJI-UHFFFAOYSA-N methyl 2h-pyridine-1-carboxylate Chemical compound COC(=O)N1CC=CC=C1 CMUHZRATLMUDJI-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8401907A SE8401907L (sv) | 1984-04-05 | 1984-04-05 | Nya fenoxipropanolaminsalter och farmaceutiska beredningar derav |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO854518L true NO854518L (no) | 1985-11-12 |
Family
ID=20355474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO854518A NO854518L (no) | 1984-04-05 | 1985-11-12 | Nye fenoksypropanolaminsalter og farmasoeytiske preparater derav. |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0209520A1 (xx) |
| JP (1) | JPS61501779A (xx) |
| KR (1) | KR860700008A (xx) |
| AP (1) | AP8500009A0 (xx) |
| AU (1) | AU4231185A (xx) |
| DD (1) | DD232488A5 (xx) |
| ES (1) | ES8609210A1 (xx) |
| GB (1) | GB2153828B (xx) |
| GR (1) | GR850840B (xx) |
| HK (1) | HK55586A (xx) |
| IL (1) | IL74611A0 (xx) |
| MA (1) | MA20396A1 (xx) |
| MY (1) | MY8600650A (xx) |
| NO (1) | NO854518L (xx) |
| PL (1) | PL252660A1 (xx) |
| PT (1) | PT80232B (xx) |
| SE (1) | SE8401907L (xx) |
| WO (1) | WO1985004579A1 (xx) |
| ZA (1) | ZA851934B (xx) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1069345A (en) * | 1963-07-19 | 1967-05-17 | Ici Ltd | New alkanolamine derivatives |
| NL130749C (xx) * | 1964-09-10 |
-
1984
- 1984-04-05 SE SE8401907A patent/SE8401907L/ not_active Application Discontinuation
-
1985
- 1985-03-14 ZA ZA851934A patent/ZA851934B/xx unknown
- 1985-03-15 IL IL74611A patent/IL74611A0/xx unknown
- 1985-03-22 GB GB08507473A patent/GB2153828B/en not_active Expired
- 1985-03-29 PL PL25266085A patent/PL252660A1/xx unknown
- 1985-04-01 AP APAP/P/1985/000009A patent/AP8500009A0/en unknown
- 1985-04-01 MA MA20618A patent/MA20396A1/fr unknown
- 1985-04-02 ES ES541850A patent/ES8609210A1/es not_active Expired
- 1985-04-03 GR GR850840A patent/GR850840B/el unknown
- 1985-04-03 JP JP60501740A patent/JPS61501779A/ja active Pending
- 1985-04-03 AU AU42311/85A patent/AU4231185A/en not_active Abandoned
- 1985-04-03 EP EP85902182A patent/EP0209520A1/en not_active Withdrawn
- 1985-04-03 WO PCT/SE1985/000159 patent/WO1985004579A1/en unknown
- 1985-04-04 DD DD85274891A patent/DD232488A5/de unknown
- 1985-04-04 PT PT80232A patent/PT80232B/pt unknown
- 1985-11-12 NO NO854518A patent/NO854518L/no unknown
- 1985-12-04 KR KR1019850700365A patent/KR860700008A/ko not_active Application Discontinuation
-
1986
- 1986-07-24 HK HK555/86A patent/HK55586A/xx unknown
- 1986-12-30 MY MY650/86A patent/MY8600650A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0209520A1 (en) | 1987-01-28 |
| JPS61501779A (ja) | 1986-08-21 |
| IL74611A0 (en) | 1985-06-30 |
| MY8600650A (en) | 1986-12-31 |
| AP8500009A0 (en) | 1986-10-01 |
| SE8401907D0 (sv) | 1984-04-05 |
| MA20396A1 (fr) | 1985-12-31 |
| GB2153828B (en) | 1986-01-22 |
| KR860700008A (ko) | 1986-01-31 |
| GR850840B (xx) | 1985-11-25 |
| WO1985004579A1 (en) | 1985-10-24 |
| GB2153828A (en) | 1985-08-29 |
| HK55586A (en) | 1986-08-01 |
| PT80232A (en) | 1985-05-01 |
| PL252660A1 (en) | 1985-11-19 |
| PT80232B (en) | 1987-03-16 |
| SE8401907L (sv) | 1985-10-06 |
| AU4231185A (en) | 1985-11-01 |
| ES8609210A1 (es) | 1986-09-01 |
| ES541850A0 (es) | 1986-09-01 |
| ZA851934B (en) | 1985-11-27 |
| GB8507473D0 (en) | 1985-05-01 |
| DD232488A5 (de) | 1986-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11384053B2 (en) | Heterocyclic compounds and their uses | |
| KR100926417B1 (ko) | Ｎ,ｎ―디메틸 이미도디카르본이미딕 디아미드의 초산염,그의 제조방법 및 그를 포함하는 약제학적 조성물 | |
| JP3810079B2 (ja) | 微粉化ネビボロールを含有する組成物 | |
| US4556678A (en) | Sustained release propranolol tablet | |
| AU762322B2 (en) | Novel galenic formulations of meloxicam for oral administration | |
| EA014739B1 (ru) | Композиция тразодона для введения один раз в день | |
| KR101226669B1 (ko) | Ｎ,ｎ－디메틸 이미도디카르본이미딕 디아미드의 디카르복실산염, 그의 제조 방법 및 그의 약제학적 조성물 | |
| KR20160046813A (ko) | 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 | |
| US20030190353A1 (en) | Low water-soluble venlafaxine salts | |
| NO873562L (no) | Hurtig-absorberende og -virkende kombinasjon av sulindac eller natriumsulindac og en base. | |
| WO2012148252A2 (es) | Cocristales ionicos con base en metformina | |
| AU2004238537A1 (en) | Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same | |
| CA3156073A1 (en) | Oral formulation of x842 | |
| JP2022549833A (ja) | 経口速放出性医薬組成物および減量治療の方法 | |
| CN108697651A (zh) | 含有普瑞巴林的口服缓释的三层片剂 | |
| NO854518L (no) | Nye fenoksypropanolaminsalter og farmasoeytiske preparater derav. | |
| CA2570096A1 (en) | Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one | |
| NO139733B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive derivater av metylamin | |
| CN101205193A (zh) | 一种醋氯芬酸与有机碱形成的盐类化合物及其组合物及用途 | |
| US6784315B2 (en) | Stilbene derivative crystal and method for producing the same | |
| WO2011126327A2 (en) | Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof | |
| KR101324425B1 (ko) | 증가된 비스포스포네이트의 생체이용률을 가지는 경구투여 약제 | |
| CN102093387B (zh) | 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物 | |
| US20210085704A1 (en) | Pharmaceutical composition comprising Canagliflozin, Process of Preparation and Use Thereof | |
| CA3232088A1 (en) | Quinoline compound sustained-release tablet and preparation method thereof |